Beam Therapeutics
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
About
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines based on its proprietary base editing technology. This technology allows for precise, single-base changes in DNA and RNA without cutting the double helix, offering a new approach to treating genetic diseases by correcting specific mutations. Teams look it up for Workflows, Biotech, MedTech.
Frequently asked
What does Beam Therapeutics do?
Beam Therapeutics is a Workflows company that offers Platform. Teams look it up for Biotech, MedTech, Genomics. It is based in Cambridge, United States and was founded in 2017. Public records show $235M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Beam Therapeutics raised?
Beam Therapeutics has raised a total of $235M in funding. The most recent round on record is Series C.
Where is Beam Therapeutics headquartered?
Beam Therapeutics is headquartered in Cambridge, United States.
When was Beam Therapeutics founded?
Beam Therapeutics was founded in 2017.
What industry does Beam Therapeutics operate in?
Beam Therapeutics operates in Workflows, Biotech, MedTech, Genomics, Drug Discovery.
What is Beam Therapeutics's current status?
Beam Therapeutics's current operating status is: Inactive.